Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Novel AR-targeted therapies in prostate cancer

Alice Bernard-Tessier • 26 Oct 2026
ESMO 2026
Genitourinary Cancer Prostate Cancer

Alice Bernard-Tessier, MD, Institut Gustave Roussy, Villejuif, France, discusses the current landscape of novel androgen receptor (AR)-targeted therapies in advanced prostate cancer, highlighting that switching between existing AR pathway inhibitors is not effective due to similar mechanisms of action and resistance. Dr Bernard-Tessier notes that integrating biomarkers such as AR mutation and amplification may help select patients for newer agents like PROTAC degraders, CYP17A1 inhibitors, or RIPTACs, but this approach remains hypothetical and awaits validation from ongoing trials. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alice Bernard-Tessier

Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
1:25
Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
Alice Bernard-Tessier • 26 Oct 2026
Mechanisms of resistance to ARPIs in prostate cancer
0:55
Mechanisms of resistance to ARPIs in prostate cancer
Alice Bernard-Tessier • 26 Oct 2026

Related Videos

Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
1:29
Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
Bérengère Salomé • 26 Oct 2026
CMV-associated adaptive NK cells influence response to IO in NMIBC
1:52
CMV-associated adaptive NK cells influence response to IO in NMIBC
Bérengère Salomé • 26 Oct 2026
Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
1:25
Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
Alice Bernard-Tessier • 26 Oct 2026
Mechanisms of resistance to ARPIs in prostate cancer
0:55
Mechanisms of resistance to ARPIs in prostate cancer
Alice Bernard-Tessier • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals